CN119032094A - 氘富集的哌啶基-甲基-嘌呤胺和有关化合物及其在治疗疾病和病症中的用途 - Google Patents
氘富集的哌啶基-甲基-嘌呤胺和有关化合物及其在治疗疾病和病症中的用途 Download PDFInfo
- Publication number
- CN119032094A CN119032094A CN202380022643.3A CN202380022643A CN119032094A CN 119032094 A CN119032094 A CN 119032094A CN 202380022643 A CN202380022643 A CN 202380022643A CN 119032094 A CN119032094 A CN 119032094A
- Authority
- CN
- China
- Prior art keywords
- certain embodiments
- compound
- deuterium
- compounds
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263296676P | 2022-01-05 | 2022-01-05 | |
| US63/296,676 | 2022-01-05 | ||
| PCT/US2023/010204 WO2023133201A1 (en) | 2022-01-05 | 2023-01-05 | Deuterium-enriched piperidinyl-methyl-purine amines and related compounds and their use in treating diseases and conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN119032094A true CN119032094A (zh) | 2024-11-26 |
Family
ID=87074217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202380022643.3A Pending CN119032094A (zh) | 2022-01-05 | 2023-01-05 | 氘富集的哌啶基-甲基-嘌呤胺和有关化合物及其在治疗疾病和病症中的用途 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12492203B2 (https=) |
| EP (1) | EP4460502A4 (https=) |
| JP (1) | JP2025504379A (https=) |
| KR (1) | KR20240158230A (https=) |
| CN (1) | CN119032094A (https=) |
| AU (1) | AU2023205553A1 (https=) |
| CA (1) | CA3242612A1 (https=) |
| IL (1) | IL314062A (https=) |
| MX (1) | MX2024008450A (https=) |
| WO (1) | WO2023133201A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021026803A1 (en) | 2019-08-14 | 2021-02-18 | Novartis Ag | Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents |
| AU2023397773A1 (en) * | 2022-12-12 | 2025-06-26 | K36 Therapeutics, Inc. | Pharmaceutical compositions containing a piperidinyl-methyl-purine amine and their use in treating diseases and conditions |
| US20250171445A1 (en) * | 2023-11-17 | 2025-05-29 | K36 Therapeutics, Inc. | Deuterium-enriched piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions |
| CN117843641B (zh) * | 2023-12-28 | 2025-04-25 | 和径医药科技（上海）有限公司 | Nsd3抑制剂及其制备方法和应用 |
| WO2025259850A1 (en) * | 2024-06-12 | 2025-12-18 | K36 Therapeutics, Inc. | Pharmaceutical compositions containing a deuterium-enriched piperidinyl-methyl-purine amine and their use in treating diseases and conditions |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010044981A2 (en) | 2008-09-18 | 2010-04-22 | Auspex Pharmaceutical ,Inc. | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| EP2463289A1 (en) * | 2010-11-26 | 2012-06-13 | Almirall, S.A. | Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors |
| WO2021026803A1 (en) | 2019-08-14 | 2021-02-18 | Novartis Ag | Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents |
| US20220380371A1 (en) | 2019-09-20 | 2022-12-01 | Novartis Ag | Mll1 inhibitors and anti-cancer agents |
| AR122159A1 (es) | 2020-05-28 | 2022-08-17 | Novartis Ag | Inhibidores de mll1 y agentes antineoplásicos |
| WO2023225154A1 (en) | 2022-05-18 | 2023-11-23 | K36 Therapeutics, Inc. | Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions |
| AU2023273656A1 (en) | 2022-05-18 | 2024-11-28 | K36 Therapeutics, Inc. | Piperidinyl-methyl-purine amine d-tartaric acid salts, crystalline forms, and their use in treating medical diseases and conditions |
| WO2023225150A1 (en) | 2022-05-18 | 2023-11-23 | K36 Therapeutics, Inc. | Piperidinyl-methyl-purine amine fumaric acid salts, crystalline forms, and their use in treating medical diseases and conditions |
| WO2023225144A1 (en) | 2022-05-18 | 2023-11-23 | K36 Therapeutics, Inc. | Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions |
| US20250361235A1 (en) | 2022-05-23 | 2025-11-27 | K36 Therapeutics, Inc. | Piperidinyl-methylpurine benzenes and related compounds and their use in treating diseases and conditions |
| US20250206740A1 (en) | 2022-05-23 | 2025-06-26 | K36 Therapeutics, Inc. | Piperidinyl-methylpurine pyrimidines and related compounds and their use in treating diseases and conditions |
| EP4583915A1 (en) | 2022-09-09 | 2025-07-16 | The Trustees Of Columbia University In The City Of New York | Methods of treating neuroendocrine prostate cancer (nepc) by inhibiting nuclear receptor binding set domain protein 2 (nsd2) |
| AU2023397773A1 (en) | 2022-12-12 | 2025-06-26 | K36 Therapeutics, Inc. | Pharmaceutical compositions containing a piperidinyl-methyl-purine amine and their use in treating diseases and conditions |
| US20250171445A1 (en) | 2023-11-17 | 2025-05-29 | K36 Therapeutics, Inc. | Deuterium-enriched piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions |
-
2023
- 2023-01-05 JP JP2024540912A patent/JP2025504379A/ja active Pending
- 2023-01-05 CA CA3242612A patent/CA3242612A1/en active Pending
- 2023-01-05 IL IL314062A patent/IL314062A/en unknown
- 2023-01-05 AU AU2023205553A patent/AU2023205553A1/en active Pending
- 2023-01-05 KR KR1020247026101A patent/KR20240158230A/ko active Pending
- 2023-01-05 WO PCT/US2023/010204 patent/WO2023133201A1/en not_active Ceased
- 2023-01-05 CN CN202380022643.3A patent/CN119032094A/zh active Pending
- 2023-01-05 EP EP23737585.2A patent/EP4460502A4/en active Pending
-
2024
- 2024-06-28 US US18/758,953 patent/US12492203B2/en active Active
- 2024-07-04 MX MX2024008450A patent/MX2024008450A/es unknown
-
2025
- 2025-10-24 US US19/368,828 patent/US20260049083A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4460502A1 (en) | 2024-11-13 |
| IL314062A (en) | 2024-09-01 |
| AU2023205553A1 (en) | 2024-07-25 |
| MX2024008450A (es) | 2024-12-06 |
| CA3242612A1 (en) | 2023-07-13 |
| US20260049083A1 (en) | 2026-02-19 |
| US20240352017A1 (en) | 2024-10-24 |
| US12492203B2 (en) | 2025-12-09 |
| EP4460502A4 (en) | 2025-12-24 |
| JP2025504379A (ja) | 2025-02-12 |
| WO2023133201A1 (en) | 2023-07-13 |
| KR20240158230A (ko) | 2024-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN119032094A (zh) | 氘富集的哌啶基-甲基-嘌呤胺和有关化合物及其在治疗疾病和病症中的用途 | |
| US11312702B2 (en) | Substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof | |
| US12364702B2 (en) | Highly active sting protein agonist compound | |
| US11420956B2 (en) | Ureas having Androgen Receptor degradation activity and uses thereof | |
| JP6402179B2 (ja) | 新規な、ＮＩＫ阻害剤としての１−（４−ピリミジニル）−１Ｈ−ピロロ［３，２−ｃ］ピリジン誘導体 | |
| CN119744262A (zh) | 哌啶基-甲基-嘌呤胺d-酒石酸盐、晶型，及其在治疗医学疾病和病况中的用途 | |
| US20250326752A1 (en) | Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions | |
| EP4039688A2 (en) | Substituted pyrrolopyrimidine and pyrazolopyrimidine as bruton's tyrosine kinase (btk) degraders | |
| US11390623B2 (en) | 6,7,8,9-tetrahydro-5H-pyrido[2,3-d]azepine dopamine D3 ligands | |
| US20240376096A1 (en) | Small molecule cyclin dependent kinase 4/6 (cdk4/6) and ikzf2 (helios) degraders and methods of use thereof | |
| US20250171445A1 (en) | Deuterium-enriched piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions | |
| US20240190842A1 (en) | Substituted quinolinone-8-carbonitrile derivatives having androgen degradation activity and uses thereof | |
| CA3054459A1 (en) | Azetidine derivative | |
| US12583839B2 (en) | PD-L1 antagonist compound | |
| TW201941774A (zh) | 二氫唏衍生物 | |
| EP2170891A1 (en) | Pyrazolopyrimidinone kinase inhibitor | |
| CN114929705B (zh) | Mll1抑制剂及抗癌剂 | |
| EP3364976B1 (en) | Piperazinyl norbenzomorphan compounds and methods for using the same | |
| HK40000945A (en) | 6,7,8,9-tetrahydro-5h-pyrido[2,3-d]azepine dopamine d3 ligands | |
| HK40000945B (en) | 6,7,8,9-tetrahydro-5h-pyrido[2,3-d]azepine dopamine d3 ligands |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |